Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 22, 2021 - Issue 7
Submit an article Journal homepage
792
Views
0
CrossRef citations to date
0
Altmetric
Letter to the editor

Response to letter to the editor. Again on IMPACT: exacerbation after abrupt discontinuation of ICS and pneumonia in fluticasone furoate-containing FDCs

Paola Rogliania Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7801-5040View further author information
ORCID Icon &
Luigino Calzettab Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, ItalyORCID Iconhttps://orcid.org/0000-0003-0456-069XView further author information
ORCID Icon
Pages 943-945 | Published online: 30 Mar 2021

References

  • Barnes NC, Jones P, Lipson DA, et al. Letter to editor – a response to: “efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review”. Expert Opin Pharmacother. 2021. DOI: 10.1080/14656566.2021.1898745.
  • Ritondo BL, Puxeddu E, Calzetta L. Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. Expert Opin Pharmacother. 2020;1–10. DOI:10.1080/14656566.2020.1845314.
  • Lipson DA, Criner GJ, Lomas DA. Single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;379(6):592–593.
  • Lipson DA, Dransfield MT, Han MK. Reply to Suissa: mortality in IMPACT: confounded by asthma? Am J Respir Crit Care Med. 2020;202(5):773–774.
  • Lipson DA, Criner GJ, Lomas DA. The authors reply to: single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–1680.
  • MeiLan KH, Lipson DA, Singh D, et al. One more time: the impact of inhaled corticosteroid withdrawal on IMPACT. Am J Respir Crit Care Med. 2020;202(9):1205–1206. .
  • Calzetta L, Ludovica Ritondo B, de Marco P, et al. Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile. 2020;1–3. DOI: 10.1080/17476348.2021.1866835.
  • Suissa S. Mortality in IMPACT: confounded by asthma? Am J Respir Crit Care Med. 2020;202(5):772–773.
  • Wedzicha JA, Banerji D, Kostikas K. Single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018. DOI: 10.1056/NEJMc1807380
  • Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. .
  • Han MK, Criner GJ, Dransfield MT, et al. The effect of inhaled corticosteroid withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study. A randomized, double-blind, multicenter clinical trial. Am J Respir Crit Care Med. 2020;202(9):1237–1243. .
  • Suissa S. Inhaled corticosteroid withdrawal in chronic obstructive pulmonary disease: can IMPACT help? Am J Respir Crit Care Med. 2020;202(9):1202–1204.
  • Dobler CC. The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD. Breathe. 2018;14(4):333–335.
  • Calzetta L, Ritondo BL, De Marco P, et al. Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and OGY studies. Expert Rev Respir Med. 2021;15(1):143–152
  • Boulet L-P, Hanania NA. The many faces of asthma-chronic obstructive pulmonary disease overlap. Curr Opin Pulm Med. 2019;25(1):1–10.
  • Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745–756. .
  • Lipson DA, Crim C, Criner GJ. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2020;201(12):1508–1516.
  • Suissa S, Ariel A. Triple therapy trials in COPD: a precision medicine opportunity. Eur Respir J. 2018;52(6):1801848.
  • Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. .
  • Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084.
  • Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973
  • Zhang Q, Li S, Zhou W, et al. Risk of pneumonia with different inhaled corticosteroids in COPD patients: a meta-analysis. Copd. 2020;17(4):462–469.
  • Yang M, Du Y, Chen H, et al. Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Int Immunopharmacol. 2019;77:105950.
  • Lipworth B, Kuo CR, Jabbal S. Current appraisal of single inhaler triple therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3003–3009.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.